NASDAQ:FTSV - Nasdaq -
95.51
+0.05 (+0.05%)
The current stock price of FTSV is 95.51 null. In the past month the price increased by 1.03%. In the past year, price increased by 413.5%.
Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP' receptor on macrophages. Forty Seven, Inc. is based in CA, United States.
Forty Seven Inc
1490 O`BRIEN DRIVE SUITE A
MENLO PARK CA 94025
CEO: Mark A. McCamish
Phone: 650-352-4150
The current stock price of FTSV is 95.51 null. The price increased by 0.05% in the last trading session.
The exchange symbol of Forty Seven Inc is FTSV and it is listed on the Nasdaq exchange.
FTSV stock is listed on the Nasdaq exchange.
Forty Seven Inc (FTSV) has a market capitalization of 4.60B null. This makes FTSV a Mid Cap stock.
Forty Seven Inc (FTSV) has a support level at 90.39 and a resistance level at 95.52. Check the full technical report for a detailed analysis of FTSV support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FTSV does not pay a dividend.
Forty Seven Inc (FTSV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.34).
ChartMill assigns a technical rating of 9 / 10 to FTSV. When comparing the yearly performance of all stocks, FTSV is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to FTSV. While FTSV has a great health rating, there are worries on its profitability.
Over the last trailing twelve months FTSV reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS increased by 37.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -558.88% | ||
ROA | -25.5% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 67% to FTSV. The Buy consensus is the average rating of analysts ratings from 6 analysts.